Xarelto (rivaroxaban) was approved by the U.S. Food and Drug Administration (FDA) in July 2011 [1].
How does Xarelto's launch compare to similar drugs?
Xarelto's entry into the market followed the approvals of other direct oral anticoagulants (DOACs). Pradaxa (dabigatran) was approved in the U.S. in October 2010 [2], making it the first DOAC available for certain indications. Eliquis (apixaban) received its first FDA approval in December 2012 [3]. This timeline shows a period of rapid innovation and introduction of new anticoagulation options for patients.
What is Xarelto used for?
Xarelto is prescribed to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation [1]. It is also used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE [1]. Additionally, it is used to prevent DVT and PE in patients who have undergone hip or knee replacement surgery [1].
When does Xarelto's patent expire?
The patent landscape for Xarelto is complex, involving multiple patents covering different aspects of the drug. Information regarding specific patent expiry dates can be found through resources that track drug patents [4]. Pharmaceutical companies often seek to extend market exclusivity through various patent strategies and litigation.
What are the main competitors to Xarelto?
Xarelto competes with other DOACs, including Pradaxa (dabigatran) and Eliquis (apixaban) [2, 3]. It also competes with warfarin, a vitamin K antagonist that has been a standard anticoagulant for many years. The choice between these medications often depends on patient-specific factors, physician preference, and cost considerations.
What clinical data supports Xarelto's use?
The approval of Xarelto was based on several large clinical trials. The ROCKET AF trial demonstrated its non-inferiority to warfarin in preventing stroke and systemic embolism in patients with atrial fibrillation [1]. Other studies evaluated its efficacy and safety in treating and preventing DVT and PE.
What are the risks associated with Xarelto?
The primary risk associated with Xarelto, like other anticoagulants, is bleeding [1]. Patients are advised to report any signs of unusual bleeding or bruising to their healthcare provider immediately. There are no routine blood tests required to monitor Xarelto's level of anticoagulation, which distinguishes it from warfarin [1].
Sources:
[1] https://www.drugpatentwatch.com/drug/xarelto
[2] https://www.drugpatentwatch.com/drug/pradaxa
[3] https://www.drugpatentwatch.com/drug/eliquis
[4] https://www.drugpatentwatch.com/